Author information
1Division of Infectious Diseases, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Baltimore, Maryland 21224, United States of America.
2Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St, Baltimore, Maryland 21205, United States of America.
3Division of General Internal Medicine, University of Washington, 325 Ninth Avenue, Seattle, Washington, 98104, United States of America.
Abstract
Access to direct acting antivirals (DAAs) may be associated with reductions in HCV viremia prevalence among people with HIV (PWH). Among 3755 PWH, estimated HCV viremia prevalence decreased by 94.0% from 36% (95% Confidence Interval [CI]: 27%, 46%) in 2009 (pre-DAA era) to 2% (95% CI: 0%, 4%) in 2021 (DAA era). Male sex, Black race and older age were associated with HCV viremia in 2009 but not in 2021. Injection drug use remained associated with HCV viremia in 2009 and 2021. Targeted interventions are needed to meet the HCV care needs of PWH who use drugs.